Sugi Predict

Sugi Predict / Compounds / SCHEMBL1334464

SCHEMBL1334464

SCHEMBL1334464

CC(C)(C)OC(=O)N1CC[C@@H](S)C1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.51
▸ RECQL P46063 1/20 0.49
▸ EPHX1 P07099 1/20 0.49
▸ USP2 O75604 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ MAPT P10636 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ GPR119 Q8TDV5 3/20 0.46
▸ NR1H2 P55055 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.44
▸ THRB P10828 1/20 0.44
▸ PTPN2 P17706 1/20 0.44
▸ PTPN1 P18031 1/20 0.44
▸ PTPN6 P29350 1/20 0.44
▸ USP30 Q70CQ3 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1334462 1.00 HPGD (0.51) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL1335011 1.00 HPGD (0.51) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL1065990 0.90 MEN1 (0.55) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL216322 0.90 MEN1 (0.55) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL2230223 0.90 MEN1 (0.55) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL1244691 0.89 HPGD (0.58) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL970631 0.85 NR1H2 (0.54) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL18549298 0.85 NR1H2 (0.54) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL28698644 0.83 NR1H2 (0.53) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL2927661 0.83 HPGD (0.60) HPGDRECQLEPHX1USP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12084445-B2 Broad-spectrum carbapenems VenatoRx Pharmaceuticals, Inc. (US) 2024-09-10 — — US disclosed
WO-2024175121-A1 α,β-UNSATURATED AMIDE COMPOUND AND USE THEREOF 希格生科（深圳）有限公司 2024-08-29 — — WO disclosed
EP-3313828-B1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-07-12 — — EP disclosed
CN-107033097-B Oxadiazole derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2022-02-08 — — CN disclosed
US-20210188851-A1 BROAD-SPECTRUM CARBAPENEMS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-06-24 — — US disclosed
CN-112513043-A Broad spectrum carbapenems 维纳拓尔斯制药公司 2021-03-16 — — CN disclosed
US-10227331-B2 Metallo-β-lactamase inhibitors MERCK SHARP & DOHME CORP. (US) 2019-03-12 — — US disclosed
US-20180179190-A1 METALLO-BETA-LACTAMASE INHIBITORS Marck Sharp & Dohme Corp. (US) 2018-06-28 — — US disclosed
EP-3313828-A1 METALLO-BETA-LACTAMASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2018-05-02 — — EP disclosed
US-9938323-B2 Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase NOVARTIS AG (CH) 2018-04-10 — — US disclosed
WO-2016071856-A1 AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE NOVARTIS AG (CH) 2016-05-12 — — WO disclosed
US-8653063-B2 N-substituted saturated heterocyclic sulfone compounds with CB2 receptor agonistic activity RAQUALIA PHARMA INC. (JP) 2014-02-18 — — US disclosed
US-8653063-B2 N-substituted saturated heterocyclic sulfone compounds with CB2 receptor agonistic activity RAQUALIA PHARMA INC. (JP) 2014-02-18 — — US disclosed
US-8653063-B2 N-substituted saturated heterocyclic sulfone compounds with CB2 receptor agonistic activity RAQUALIA PHARMA INC. (JP) 2014-02-18 — — US disclosed
US-20110281840-A1 N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY ASKAT INC. (JP) 2011-11-17 — — US disclosed
US-20110281840-A1 N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY ASKAT INC. (JP) 2011-11-17 — — US disclosed
US-20110281840-A1 N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY ASKAT INC. (JP) 2011-11-17 — — US disclosed
EP-2379533-A1 N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY RaQualia Pharma Inc (JP) 2011-10-26 — — EP disclosed
WO-2010084767-A1 N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY RAQUALIA PHARMA INC. (JP) 2010-07-29 — — WO disclosed
WO-2010084767-A1 N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY RAQUALIA PHARMA INC. (JP) 2010-07-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281840-A1 N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY CNR1, CNR2, NPSR1 HPGD 1414/4885RECQL 3175/4885EPHX1 1132/4885
US-10227331-B2 Metallo-β-lactamase inhibitors ALPI, GAA, ZFX HPGD 1996/4885RECQL 510/4885EPHX1 1171/4885
US-20180179190-A1 METALLO-BETA-LACTAMASE INHIBITORS ALPI, GAA, ZFX HPGD 1960/4885RECQL 501/4885EPHX1 1149/4885
US-20210188851-A1 BROAD-SPECTRUM CARBAPENEMS MGAM, ALPI, SI HPGD 1250/4885RECQL 1157/4885EPHX1 3123/4885
US-12084445-B2 Broad-spectrum carbapenems MGAM, ALPI, SI HPGD 1250/4885RECQL 1157/4885EPHX1 3123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.